Heart rate and adverse outcomes in patients with prevalent atrial fibrillation

Giorgio Moschovitis 1,2, Linda S B Johnson 3,4,5 Steffen Blum,4,5 Stefanie Aeschbacher 1,5, Maria Luisa De Perna,1 Alberto Pagnamenta,6 Patrizia Assunta Mayer Melchiorre,1 Alexander P Benz,2 Richard Kobza,7 Marcello Di Valentino,8,9 Christine S Zuern,4,5 Angelo Auricchio,10 Giulio Conte 1,10 Nicolas Rodondi,11,12 Manuel R Blum,11,12 Juerg H Beer,13,14 Michael Kühne,4,5 Stefan Osswald,4,5 David Conen,2 BEAT-AF and Swiss-AF investigators

ABSTRACT

Objective The optimal target heart rate in patients with prevalent atrial fibrillation (AF) is not well defined. The aim of this study was to analyse the associations between heart rate and adverse outcomes in a large contemporary cohort of patients with prevalent AF.

Methods From two prospective cohort studies, we included stable AF outpatients who were in AF on the baseline ECG. The main outcome events assessed during prospective follow-up were heart failure hospitalisation, stroke or systemic embolism and death. The associations between heart rate and adverse outcomes were evaluated using multivariable Cox regression models.

Results The study population consisted of 1679 patients who had prevalent AF at baseline. Mean age was 74 years, and 24.6% were women. The mean heart rate on the baseline ECG was 78 (±19) beats per minute (bpm). The median follow-up was 3.9 years (IQR 2.2–5.0). Heart rate was not significantly associated with heart failure hospitalisation (adjusted HR (aHR) per 10 bpm increase, 1.00, 95% CI 0.94 to 1.07, p=0.95), stroke or systemic embolism (aHR 0.95, 95% CI 0.84 to 1.07, p=0.38) or death (aHR 1.02, 95% CI 0.95 to 1.09, p=0.66). There was no evidence of a threshold effect for heart rates <60 bpm or ≥100 bpm.

Conclusions In this large contemporary cohort of outpatients with prevalent AF, we found no association between heart rate and adverse outcome events. These data are in line with recommendations that strict heart rate control is not needed in otherwise stable outpatients with AF.

INTRODUCTION

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia in the general population, and its prevalence is rapidly increasing.1 AF is associated with an increased risk of heart failure, stroke and death.2–4 Treatment options for AF patients with prevalent AF on the ECG include both rhythm and rate control, as neither has been shown to be superior for patients eligible for both options.5–8 While an increased heart rate has been consistently associated with mortality and morbidity in sinus rhythm patients,9–11 much less information is available on the prognostic value of heart rate in patients with prevalent AF. In the relatively small Rate Control Efficacy in Permanent Atrial Fibrillation: a Comparison between Lenient versus Strict Rate Control II (RACE-II) trial, lenient rate control was not inferior to strict rate control for preventing the primary composite outcome of cardiovascular death, hospitalisation for heart failure, stroke, systemic embolism, bleeding and life-threatening arrhythmic events in patients with permanent AF.9 Pooled data from RACE and AFFIRM did not show a significant difference in the primary endpoint (composite of...
mortality, cardiovascular hospitalisation and myocardial infarction) between a more strict (target heart rate <80 beats per minute (bpm)) vs a more lenient (heart rate <100bpm) rate control. In another analysis, heart rate during AF was not associated with mortality, in contrast to heart rate during sinus rhythm.

Current guidelines propose an initial resting heart rate target of <110bpm mainly to improve haemodynamic stability, reduce symptoms and preserve left ventricular function. However, for the large group of AF patients who are haemodynamically stable and mostly asymptomatic, more data are needed to determine the optimal heart rate target.

We, therefore, conducted the current analysis to assess the associations between heart rate and several adverse outcome events in a large cohort of contemporary outpatients treated in standard care with prevalent AF during the baseline examination.

**MATERIALS AND METHODS**

**Patient population**

The study population was derived from two similar and ongoing prospective cohort studies: Swiss AF (Swiss-AF, n=2415) and Basel AF (BEAT-AF, n=1546) cohort study. We excluded subjects who were not in AF or atrial fibrillation at the time of the baseline examination (n=2207) or subjects with missing data on heart rhythm (n=27) or other covariates (n=48). The final study population consisted of 1679 individuals with AF at the baseline examination.

Written informed consent has been obtained from the participants (or their guardians).

Methodology and data collection in Swiss-AF and BEAT-AF were very similar and have been previously described in detail. Both studies have recruited from multiple sites in Switzerland, with enrolment during 2010–2014 for BEAT-AF and 2014–2017 for Swiss-AF. In both cohorts, patients had to be 65 years or older and have established, previously documented AF. A convenience sample of patients aged 45–64 years was enrolled in both cohorts to evaluate the effects of AF on the active workforce. Patient with an acute illness in the past 4 weeks could only be enrolled after clinical stabilisation. Patients with transient AF in connection with an acute illness or surgery were excluded. Patients enrolled in BEAT-AF could not participate in Swiss-AF.

**Baseline measurements and follow-up assessments**

Baseline examination included the same case report form in both cohorts. Heart rhythm and rate were obtained from a standard resting 12-lead ECG (BEAT-AF) or 16-lead ECG (Swiss-AF) during a 10s registration. Weight (kg) and height (metre (m)) were directly measured. Body mass index (BMI) was calculated as kg/m². Smoking status was categorised into current smokers, former smokers and never smokers. Regular physical activity was defined as physical exercise on a regular basis (yes/no). Alcohol consumption was calculated as number of standard unit drinks per day. AF was classified according to the 2010 guidelines of the European Society of Cardiology into paroxysmal (self-terminating), persistent (lasting ≥7 days or requiring termination by electrical or pharmacological cardioversion) or permanent AF (accepted by patient and physician). Antiarrhythmic drugs were categorised according to the Vaughan-Williams classification: class 1 (sodium-channel blocker), class 2 (beta-blockers), class 3 (amiodarone, sotalol and dronedarone) and class 4 (non-dihydropyridine calcium-channel blocker). History of coronary artery disease (CAD) was defined as a history of myocardial infarction, percutaneous coronary angioplasty or coronary by-pass graft surgery. After an in-person baseline visit in both cohorts, follow-up was conducted annually by mail and phone interviews in BEAT-AF, and by in-person visits in Swiss-AF.

**Clinical outcome events**

Both cohorts used the same definitions for all clinical adverse outcome events. All events were validated by two physicians in a standardised way, on the basis of all available information. In cases of discordant assessments, a third reviewer physician was consulted. Incident heart failure hospitalisation was defined as a hospitalisation for congestive heart failure that was associated with at least one overnight stay, or a congestive heart failure exacerbation that led to an extension of an existing hospitalisation. Stroke was defined as an acute focal neurological deficit of vascular origin, confirmed by imaging (CT or MRI) or autopsy, and systemic embolism was defined as evidence of abrupt occlusion of a systemic artery consistent with an embolic event. Detailed outcome event definitions are provided in online supplemental table 1.

**Patient and public involvement**

Patients and public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

**Statistical analysis**

Baseline characteristics are presented across quartiles of heart rate. Differences across quartiles were analysed using analysis of variance for normally distributed continuous variables, Kruskal-Wallis tests for non-normally distributed continuous variables and \( \chi^2 \) tests for categorical variables.

Follow-up analyses to evaluate the associations between heart rate and clinical outcome events were performed using Cox regression models adjusted for two prespecified set of covariates. In model 1, we adjusted for age and sex. In model 2, we additionally adjusted for BMI, history of hypertension, history of diabetes mellitus, history of CAD, history of stroke or transient ischaemic attack, history of heart failure, type of AF (paroxysmal and persistent vs permanent), smoking status, alcohol consumption, physical activity, use of antiarrhythmic medication according to the Vaughan-Williams classification, digoxin and oral...
Arrhythmias and sudden death
anticoagulation. The associations between heart rate and outcome events were analysed per 10 bpm as well as by prespecified categories for low heart rate defined as <60 bpm, or high heart rate defined as ≥100 bpm.

The shape of the association of heart rate with the heart failure hospitalisation, stroke and mortality was further assessed by including a quadratic term into model 2. Interaction between heart rate and sex or history of heart failure at baseline was assessed by including a multiplicative interaction parameter in model 2. Finally, we further assessed the association between heart rate and heart failure hospitalisation and stroke or systemic embolism after accounting for the competing risk of mortality using competing risk regression as described by Fine and Gray. The proportional hazards assumption was assessed visually using Nelson-Aalen plots and found to be valid for all models. A two-sided p<0.05 was considered statistically significant. All analyses were performed with Stata SE V. 15.1. Data are not available.

RESULTS
The mean age of the study population (n=1679) was 74 years (SD 9 years), 24.6% were women, and 51.4% had permanent AF. The mean heart rate at the time of enrollment was 78 bpm (SD 19 bpm, range 31–160 bpm); 9.7% (n=162) had a heart rate <60 bpm, and 12.0% (n=201) a heart rate ≥100 bpm. The median follow-up duration was 3.9 years (IQR 2.2–5.0). Baseline characteristics stratified by quartiles of heart rate are reported in Table 1.

Heart rate and heart failure hospitalisation
During the follow-up, there were 301 heart failure hospitalisations, corresponding to an incidence rate of 47.4 (95% CI 42.3 to 53.0) per 1000 person-years. There was no significant association between heart rate and heart failure hospitalisation using either Cox regression models or competing risks regression (tables 2 and 3). We found no evidence of a nonlinear association (p for quadratic term=0.47), nor was there a significant association between heart rates <60 or ≥100 bpm with heart failure hospitalisation (table 2). There was no evidence of interaction between heart rate and either sex (p for interaction=0.99) or history of heart failure (p for interaction=0.22).

Heart rate and stroke or systemic embolism
There were 96 stroke or systemic embolism events during follow-up, corresponding to an incidence rate of 14.4

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Baseline characteristics by quartiles of baseline heart rate</th>
</tr>
</thead>
<tbody>
<tr>
<td>Characteristics (n=1679)</td>
<td>Quartile 1 (n=395)</td>
</tr>
<tr>
<td>Heart rate range, bpm</td>
<td>31–64</td>
</tr>
<tr>
<td>Age, years</td>
<td>75.5 (8.5)</td>
</tr>
<tr>
<td>Female sex, %</td>
<td>21.8</td>
</tr>
<tr>
<td>Body mass index, kg/m²</td>
<td>27.5 (4.6)</td>
</tr>
<tr>
<td>History of coronary artery disease, %</td>
<td>38.7</td>
</tr>
<tr>
<td>History of stroke or TIA, %</td>
<td>22.5</td>
</tr>
<tr>
<td>History of hypertension, %</td>
<td>76.5</td>
</tr>
<tr>
<td>History of heart failure, %</td>
<td>39.5</td>
</tr>
<tr>
<td>History of diabetes, %</td>
<td>21.0</td>
</tr>
<tr>
<td>Smoking status, %</td>
<td></td>
</tr>
<tr>
<td>Current</td>
<td>5.6</td>
</tr>
<tr>
<td>Former</td>
<td>53.2</td>
</tr>
<tr>
<td>Never</td>
<td>41.3</td>
</tr>
<tr>
<td>Oral anticoagulation, %</td>
<td>93.9</td>
</tr>
<tr>
<td>Antiarrhythmic drugs*, %</td>
<td></td>
</tr>
<tr>
<td>Class 1c</td>
<td>1.0</td>
</tr>
<tr>
<td>Class 2</td>
<td>65.8</td>
</tr>
<tr>
<td>Class 3</td>
<td>8.1</td>
</tr>
<tr>
<td>Class 4</td>
<td>27.6</td>
</tr>
<tr>
<td>Use of digoxin, %</td>
<td>9.1</td>
</tr>
<tr>
<td>Regular physical activity, %</td>
<td>42.4</td>
</tr>
<tr>
<td>Alcohol consumption, standard units/day</td>
<td>0.80 (1.4)</td>
</tr>
</tbody>
</table>

Normally distributed continuous data are presented as means (SD), qualitative data are presented as absolute numbers (percentages). Non-normally distributed data (alcohol use) are presented as median (IQR).

*Vaughan Williams classifications: class 1c, sodium-channel blockers, class 2=beta-blockers, class 3=amiodarone, sotalol and dronedarone; class 4=non-dihydropyridine calcium-channel blockers.

TIA, transient ischaemic attack.
We found no evidence of an association between heart rate and stroke or systemic embolism, in either Cox or competing risks models (tables 2 and 3). The number of events among subjects with high heart rates was very small (n=3), and associations with stroke were not assessed in this stratum. There was no evidence of a nonlinear relationship (p=0.30). We found no evidence of interaction between sex and heart rate (p for interaction=0.85) or history of heart failure status (p for interaction=0.11).

Heart rate and mortality

There were 283 deaths during follow-up (incidence rate 41.4 (95% CI 36.9 to 46.5) per 1000 person-years. Heart rate was not associated with mortality, either as a continuous variable or among subjects with low or high heart rates (table 2), and there was no evidence of a nonlinear association (p=0.20). We found no evidence of an interaction between heart rate and either sex (p for interaction=0.77) or history of heart failure status (p for interaction=0.17).

### DISCUSSION

In this large cohort of stable outpatients with prevalent AF at the time of enrolment, we found no significant associations of heart rate with the risks of incident heart failure hospitalisation, stroke or systemic embolism and death. Most patients had a resting heart rate between 60 and 100 bpm, likely a reflection of the inclusion of stable outpatients in this contemporary cohort, who would have received treatment if they had more extreme heart rates. There was no evidence of nonlinear associations, and neither a heart rate <60 bpm nor a heart rate ≥100 bpm was significantly associated with adverse outcomes.

### Table 2: Cox regression models for the associations of resting heart rate with adverse outcomes

<table>
<thead>
<tr>
<th></th>
<th>Events</th>
<th>Incidence rate, per 1000 (95% CI)</th>
<th>Model 1 HR 95% CI</th>
<th>P value</th>
<th>Model 2 HR 95% CI</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart failure hospitalisation</td>
<td>301</td>
<td>47.3 (42.3 to 53.0)</td>
<td>0.98 (0.92 to 1.05)</td>
<td>0.57</td>
<td>1.00 (0.94 to 1.07)</td>
<td>0.95</td>
</tr>
<tr>
<td>Per 10 bpm increase</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;60 bpm</td>
<td>31</td>
<td>52.3 (36.8 to 74.4)</td>
<td>0.97 (0.67 to 1.41)</td>
<td>0.88</td>
<td>0.92 (0.63 to 1.34)</td>
<td>0.65</td>
</tr>
<tr>
<td>≥100 bpm</td>
<td>33</td>
<td>39.6 (28.2 to 55.8)</td>
<td>1.03 (0.72 to 1.49)</td>
<td>0.85</td>
<td>1.17 (0.81 to 1.70)</td>
<td>0.40</td>
</tr>
<tr>
<td>Total mortality</td>
<td>283</td>
<td>41.4 (36.9 to 46.5)</td>
<td>0.99 (0.93 to 1.06)</td>
<td>0.82</td>
<td>1.02 (0.95 to 1.09)</td>
<td>0.66</td>
</tr>
<tr>
<td>Per 10 bpm increase</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;60 bpm</td>
<td>30</td>
<td>46.4 (32.8 to 66.4)</td>
<td>0.96 (0.65 to 1.40)</td>
<td>0.82</td>
<td>0.89 (0.60 to 1.31)</td>
<td>0.55</td>
</tr>
<tr>
<td>≥100 bpm</td>
<td>25</td>
<td>28.3 (19.1 to 41.7)</td>
<td>0.85 (0.56 to 1.29)</td>
<td>0.45</td>
<td>0.94 (0.62 to 1.44)</td>
<td>0.79</td>
</tr>
<tr>
<td>Stroke or systemic embolism</td>
<td>96</td>
<td>14.4 (11.8 to 17.6)</td>
<td>0.93 (0.83 to 1.05)</td>
<td>0.27</td>
<td>0.95 (0.84 to 1.07)</td>
<td>0.38</td>
</tr>
<tr>
<td>Per 10 bpm increase</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;60 bpm</td>
<td>10</td>
<td>16.0 (8.6 to 29.7)</td>
<td>0.98 (0.81 to 1.90)</td>
<td>0.95</td>
<td>0.95 (0.48 to 1.84)</td>
<td>0.87</td>
</tr>
</tbody>
</table>

Model 1 is adjusted for age and sex.
Model 2 is adjusted for model 1+ body mass index, physical activity, smoking status (never, former or current), type of AF (paroxysmal and persistent vs permanent), alcohol use (log-transformed), history of stroke/TIA, history of heart failure, hypertension, diabetes, the use of beta-blockers, non-dihydropyridine calcium-channel blockers, class 1c antiarrhythmic drugs, class 3 antiarrhythmic drugs, digoxin and oral anticoagulation.
AF, atrial fibrillation; TIA, transient ischaemic attack.

### Table 3: Competing risks regression analyses for incident heart failure and stroke by heart rate

<table>
<thead>
<tr>
<th></th>
<th>Model 1</th>
<th></th>
<th>Model 2</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>SHR 95% CI</td>
<td>P value</td>
<td>SHR 95% CI</td>
<td>P value</td>
</tr>
<tr>
<td>Heart failure hospitalisation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Per 10 bpm increase</td>
<td>0.98 (0.91 to 1.05)</td>
<td>0.54</td>
<td>0.99 (0.92 to 1.06)</td>
<td>0.78</td>
</tr>
<tr>
<td>&lt;60 bpm</td>
<td>0.99 (0.68 to 1.44)</td>
<td>0.95</td>
<td>0.95 (0.65 to 1.39)</td>
<td>0.79</td>
</tr>
<tr>
<td>≥100 bpm</td>
<td>1.05 (0.72 to 1.53)</td>
<td>0.79</td>
<td>1.16 (0.79 to 1.71)</td>
<td>0.44</td>
</tr>
<tr>
<td>Stroke or systemic embolism</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Per 10 bpm increase</td>
<td>0.93 (0.84 to 1.03)</td>
<td>0.17</td>
<td>0.94 (0.84 to 1.06)</td>
<td>0.30</td>
</tr>
<tr>
<td>&lt;60 bpm</td>
<td>1.01 (0.52 to 1.93)</td>
<td>0.99</td>
<td>0.97 (0.49 to 1.90)</td>
<td>0.92</td>
</tr>
</tbody>
</table>

Model 1 is adjusted for age and sex.
Model 2 is adjusted for model 1+ body mass index, physical activity, smoking status (never, former or current), type of AF (paroxysmal and persistent vs permanent), alcohol use (log-transformed), history of stroke/TIA, history of heart failure, hypertension, diabetes, the use of beta-blockers, non-dihydropyridine calcium-channel blockers, class 1c antiarrhythmic drugs, class 3 antiarrhythmic drugs, digoxin and oral anticoagulation.
Includes 1679 subjects, with 162 subjects with heart rate <60and 201 subjects with heart rate ≥100 bpm.
AF, atrial fibrillation; SHR, sub-HR; TIA, transient ischaemic attack.
The Early Treatment of Atrial Fibrillation for Stroke Prevention Trial (EAST-AFNET) recently found that early rhythm control treatment improved adverse clinical outcomes in patients with early AF. Whether these data apply to a wider group of AF patients is currently unclear. In addition, in symptomatic patients with uncontrolled AF, rate or rhythm control are important to improve haemodynamic stability and AF-related symptoms and to prevent or reverse systolic dysfunction. However, in daily clinical practice, the great majority of elderly patients with AF do not complain about AF-related symptoms and are haemodynamically stable, despite widely varying heart rates, and despite variable use of rate-controlling agents. Our data do not apply to the first group of patients, but do suggest that in the latter population, more stringent heart rate control is not needed for the prevention of adverse outcomes. The present study suggests that this concept is applicable to a broad group of elderly patients with a high prevalence of comorbidities.

In previous studies, there has been some controversy regarding the prognostic significance of heart rate. For example, a higher heart rate on the baseline ECG was associated with incident heart failure in a study where patients in AF and sinus rhythm were analysed together. On the other hand, heart rate during AF was not associated with all-cause or cardiovascular mortality in a pooled analysis of two cohorts, in contrast to heart rate during sinus rhythm. Similarly, in patients with prevalent AF, heart rate was not associated with the composite endpoint of death, cardiovascular hospitalisation and myocardial infarction after multivariable adjustment. Our study adds to this literature, by confirming that in stable contemporary outpatients with prevalent AF, heart rate was not associated with adverse outcomes. In addition, we found no evidence of a threshold effect for heart rates <60 bpm or >100 bpm, considered adequate heart rate thresholds by current guidelines.

Our data are in line with the RACE-II trial, where a strict rate control strategy (<80 bpm at rest) was not superior to a lenient rate control strategy (<110 bpm at rest). The mean heart rates of our study patients were in the same range as in RACE-II, where the mean heart rate achieved was 93 bpm and 76 bpm in the lenient and strict rate control arm, respectively. While one of the few randomised trials in this field, the sample size in RACE-II was relatively small, the primary endpoint included heterogeneous outcomes, and patients with a history of stroke were excluded, such that our study may provide some reassurance with regard to the generalisability of these findings.

Strengths and limitations
Strengths of this analysis include the relatively large sample size of contemporary patients with AF, a limited amount of missing data and a relatively long and complete follow-up. However, there are some potential limitations that should be considered when interpreting our data. First, as in any observational study, we cannot assess causality and residual confounding may persist even after extensive multivariable adjustment. Moreover, some residual confounding due to change in confounders during follow-up may also exist, but given that adjustment for the covariates at baseline had little effect on the results, we do not consider that any such confounding would have significantly altered these results. Second, heart rate thresholds (<60 and ≥100 bpm) were chosen to represent commonly used definitions of bradycardia and tachycardia. Our study was not sufficiently powered to determine whether more extreme heart rates are significantly associated with adverse outcome events. In addition, many AF patients with more extreme heart rates are symptomatic and require interventions anyway. Third, the heart rate was derived from one 10s ECG strip at baseline. While this is the current clinical standard in most stable patients with AF, it is possible that a more detailed assessment of the heart rate using longer recording times (eg, 24-hour Holter recording) may provide different associations with clinical outcomes in this population. It is also possible that related parameters such as heart rate variability may improve risk stratification, and further studies are needed in this area. Nevertheless, current clinical practice still heavily relies on short heart rate assessments.

CONCLUSIONS
In conclusion, in this large cohort of patients with prevalent AF, heart rate was not associated with heart failure hospitalisation, stroke or systemic embolism and death. These data are in line with recommendations that strict heart rate control is not needed in most stable outpatients with AF.

Author affiliations
1 Division of Cardiology, Regional Hospital of Lugano, Repubblica e Cantone Ticino Ente Ospedaliero Cantonale, Lugano, Ticino, Switzerland
2 Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada
3 Clinical Sciences, Lund University, Malmö, Sweden
4 Division of Cardiology, University Hospital Basel, Basel, Switzerland
5 Cardiovascular Research Institute Basel, University Hospital Hospital Basel, Basel, Switzerland
6 Unit of Clinical Epidemiology, Repubblica e Cantone Ticino Ente Ospedaliero Cantonale, Bellinzona, Ticino, Switzerland
7 Cardiology Division, Heart Center, Luzerner Kantons spitale, Luzern, Luzern, Switzerland
8 Division of Cardiology, Ospedale San Giovanni, Repubblica e Cantone Ticino Ente Ospedaliero Cantonale, Bellinzona, Ticino, Switzerland
9 Faculty of Biomedical Sciences, Universita della Svizzera Italiana, Lugano, Ticino, Switzerland
10 Division of Cardiology, Fondazione Cardiocentro Ticino, Lugano, Ticino, Switzerland
11 Institute of Primary Health Care, University of Bern, Bern, Switzerland
12 Department of General Medicine, Inselspital University Hospital Bern, Bern, Switzerland
13 Department of Medicine, Baden Cantonal Hospital, Baden, Aargau, Switzerland
14 Center for Molecular Cardiology, University of Zurich, Zurich, Switzerland

Twitter Linda S B Johnson @ljsMD
Acknowledgements We would like to thank all the patients who participated to the study.
Contributors GM and DC conceived this analysis. GM, SB, SA, MLDP, PAMM, RK, MDV, CSZ, AA, GC, NR, MRB, JHB, MK, SO and DC contributed to data collection. LSBJ and DC planned the statistical methodology, which LSBJ performed and reported. GM and LSBJ drafted the manuscript. All coauthors contributed critical revisions to the manuscript. All authors approved the final version of the manuscript. GM, LSBJ and DC are responsible for the overall content of the work as guarantors.

Funding BEAT-AF has been supported by the Swiss National Science Foundation (PP00P3_159322), the Swiss Heart Foundation, the University Hospital of Basel, Roche Diagnostics, Boehringer Ingelheim, Sanofi-Aventis, Merck Sharp & Dome, Bayer, Daichichi-Sankyo and Pfizer/Bristol-Myers Squibb. Swiss-AF has been supported by grants of the Swiss National Science Foundation (grant numbers 33CS30_148474 and 33CS30_177520), the Foundation for Cardiovascular Research Basel (FCVR), the University of Basel and Roche Diagnostics. DC holds a McMaster University Department of Medicine Mid-Career Research Award. LSBJ is supported by governmental funding within the Swedish National Health Services, as well as by the Swedish Society of Medicine, the Swedish Heart and Lung Foundation, the Swedish Heart and Lung Association and the Bergvist Foundation.

Competing interests Disclosures/conflicts of interest outside of the submitted work, are reported within the manuscript. GM has received consultant fees for taking part to advisory boards from Novartis and Astra Zeneca outside of the submitted work. RK receives institutional grants from Abbott, Biosense-Webster, Boston-Scientific, Biotronik, Medtronic and Sis-Medical. CSZ reports a research grant from Medtronic and honoraria from Vifor Pharma and Novartis. AA has served as consultant to Boston Scientific, Backbeat, Biosense Webster, Caidec, Corvia, Miropro CRT, EPD-Philips and RadiRchulfe; he received speaker fees from Boston Scientific, Medtronic, and Microport; he participates in clinical trials sponsored by Boston Scientific, Medtronic, EPD-Philips; and he has intellectual properties with Boston Scientific, Biosense Webster, and Micropot CRM. JHB reports grants from the Swiss National Foundation of Science, The Swiss Heart Foundation. MK has served on the speaker's bureau for Boston Scientific, St. Jude Medical and Biotronik; he has received lecture/consulting fees from Sorin, Boehringer Ingelheim, Bayer, Sanofi Aventis, Novartis, Medtronic, Pfizer-BMS and has received unrestricted grants from Bayer and Pfizer-BMS, he is a proctor for Medtronic (Cryoballon), DC has received consultant/speaker fees from Servier Canada and Roche Diagnostics, Switzerland, outside of the submitted work.

Patient consent for publication Not required.

Ethics approval The study comply with the Declaration of Helsinki. The research protocol has been approved by the locally appointed ethics committee.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement No data are available.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Giorgio Moschovitis http://orcid.org/0000-0002-4043-8061
Linda S B Johnson http://orcid.org/0000-0002-2249-8220
Stefanie Aeschbacher http://orcid.org/0000-0001-8134-2421
Giulio Conte http://orcid.org/0000-0003-2248-3456

REFERENCES
Supplementary Material

Heart rate and adverse outcomes in patients with prevalent atrial fibrillation

Giorgio Moschovitis, MD,*1,2 Linda Johnson, MD, PhD,*2,3 Steffen Blum, MD, PhD,4,5 Stefanie Aeschbacher, PhD,4,5 Maria Luisa De Perna, MD,1 Alberto Pagnamenta, MD, MSc,6 Patrizia Mayer-Melchiorre, MD,1 Alexander P. Benz, MD,2 Richard Kobza, MD,7 Marcello Di Valentino, MD,8,9 Christine S. Zuern, MD,4,5 Angelo Auricchio, MD, PhD,10 Giulio Conte, MD, PhD,10 Nicolas Rodondi, MD,11,12 Manuel R. Blum, MD, MSc,11,12 Juerg H. Beer, MD,13,14 Michael Kühne, MD,4,5 Stefan Osswald, MD,4,5 David Conen, MD, MPH2, on behalf of the BEAT-AF and Swiss-AF investigators**

*contributed equally and are shared first authors

Supplemental Table S1  Definition of outcome events
**Swiss-AF Investigators**


Principal Investigator: Stefan Osswald; Local Principal Investigator: Michael Kühne

University Hospital Bern: Faculty: Drahomir Aujesky, Urs Fischer, Juerg Fuhrer, Laurent Roten, Simon Jung, Heinrich Mattle; Research fellows: Luise Adam, Carole Elodie Aubert, Martin Feller, Axel Loewe, Elisavet Moutzouri, Claudio Schneider; Study nurses: Tanja Flückiger, Cindy Groen, Lukas Hellrigl, Alexandra Nuoffer, Damiana Rakovic, Nathalie Schwab, Rylana Wenger. Local Principal Investigator: Nicolas Rodondi

Stadtspital Triemli Zurich: Christopher Beynon, Roger Dillier, Michèle Deubelbeiss, Franz Eberli, Christine Franzini, Isabel Juchli, Claudia Liedtke, Jacqueline Nadler, Thayze Obst, Jasmin Roth, Fiona Schlomowitsch, Xiaoye Schneider, Katrin Studerus, Noreen Tynan, Dominik Weishaupt. Local Principal Investigator: Andreas Müller

Kantonsspital Baden: Simone Fontana, Silke Kuest, Karin Scheuch, Denise Hischier, Nicole Bonetti, Alexandra Grau, Jonas Villinger, Eva Laube, Philipp Baumgartner, Mark Filipovic, Marcel Frick, Giulia Montrasio, Stefanie Leuenberger, Franziska Rutz. Local Principal Investigator: Jürg-Hans Beer

Cardiocentro Lugano: Angelo Auricchio, Adriana Anesini, Cristina Camporini, Giulio Conte, Maria Luce Caputo, Francois Regoli. Local Principal Investigator: Tiziano Moccetti

Kantonsspital St. Gallen: Roman Brenner, David Altmann, Michaela Gemperle. Local Principal Investigator: Peter Ammann

Hôpital Cantonal Fribourg: Mathieu Firmann, Sandrine Foucras, Martine Rime. Local Principal Investigator: Daniel Hayoz
Luzerner Kantonsspital: Benjamin Berte, Virgina Justi, Frauke Kellner-Weldon, Brigitta Mehmann, Sonja Meier, Myriam Roth, Andrea Ruckli-Kaeppele, Ian Russi, Kai Schmidt, Mabelle Young, Melanie Zbinden. Local Principal Investigator: Richard Kobza

Ente Ospedaliero Cantonale Lugano: Jane Frangi-Kultalahti, Anica Pin, Luisa Vicari. Local Principal Investigator: Giorgio Moschovitis

University Hospital Geneva: Georg Ehret, Hervé Gallet, Elise Guillermet, Francois Lazeyras, Karl-Olof Lovblad, Patrick Perret, Philippe Tavel, Cheryl Teres. Local Principal Investigator: Dipen Shah

University Hospital Lausanne: Nathalie Lauriers, Marie Méan, Sandrine Salzmann. Local Principal Investigator: Jürg Schläpfer

Bürgerspital Solothurn: Andrea Grêt, Jan Novak, Sandra Vitelli. Local Principal Investigator: Frank-Peter Stephan

Ente Ospedaliero Cantonale Bellinzona: Jane Frangi-Kultalahti, Augusto Gallino. Local Principal Investigator: Marcello Di Valentino

University of Zurich/University Hospital Zurich: Fabienne Witassek, Matthias Schwenkglenks

Medical Image Analysis Center AG Basel: Jens Würfel (Head), Anna Altermatt, Michael Amann, Petra Huber, Esther Ruberte, Tim Sinnecker, Vanessa Zuber

Clinical Trial Unit Basel: Michael Coslovsky (Head), Pascal Benkert, Gilles Dutilh, Milica Markovic, Pia Neuschwander, Patrick Simon

Schiller AG Baar: Ramun Schmid
Supplemental Table S1  Definition of outcome events

**Hospitalization for acute heart failure**

Hospitalization for acute heart failure is defined as: any hospitalization for acute heart failure that is associated with at least one overnight stay. If it’s not clear whether the reason for a patient’s hospitalization is acute heart failure or not, this event/incidence should in doubt be classified as acute heart failure.

The following references mentioned under clinical examination, or in the progress entry could be used as an indication for heart failure: leg swelling/leg edema, distension of the neck veins, positive hepato-jugular reflux, rales and 3rd heart sound.

**All-cause mortality**

Deaths were classified as cardiovascular or non-cardiovascular origin. All deaths were assumed to be of cardiovascular origin unless a non-cardiovascular cause could be clearly established.

**Stroke or systemic embolism**

Stroke was defined as an acute focal neurologic deficit of vascular origin, confirmed by imaging or autopsy.

Stroke was categorized as ischemic, hemorrhagic or as having an unknown cause.

A systemic arterial embolism will be considered to have occurred where there is clear evidence of abrupt occlusion of a systemic artery consistent with an embolic event. Pulmonary embolism or deep vein thrombosis should not be reported.